SLAS2016 Short Courses

Derivation of iPS Cells and Maintenance Techniques of iPS-Derived Cells for Use in High-Throughput Screening and Disease Modeling

Course Description

This discussion based course will provide general overview on the basic stem cells biology and laboratory techniques used to derive and maintain human induced pluripotent stem cell (iPS). The application of using iPS- derived lines in high-throughput screening (HTS) and disease modeling. Additional topics will include manual and semi-automated reprogramming techniques, characterization of iPS assays and Embryonic Stem cells (ES) protocols and HTS strategy with emphasis on the derivation of neural and other lineage cell lines.

Who Should Attend:

How You Will Benefit From This Course:

Course Topics:

Instructor Name(s)/Affiliation(s):

David J Kahler — NYU Langone Medical Center

Instructor Bios:

David J Kahler

David Kahler earned his Ph.D. in Molecular Medicine and Immunology from the Medical College of Georgia in the lab of Andrew Mellor, where he studied the phenotype, function, and lineage of a rare subset of immunomodulatory dendritic cells found in humans and mice. While at the New York Stem Cell Foundation, Dr. Kahler served as the Director of the Flow Cytometry Core and Drug Discovery laboratories, and as Director of Laboratory Automation where he developed FCM/FACS based and automated technologies for the derivation, characterization and maintenance of human IPSC lines. Currently he is providing experimental design, assay development and data analysis support to clients of the RNAi HTS Core Laboratory at the NYU Langone School of Medicine.

Kamal Garcha, Ph.D.

Kamal Garcha earned his Ph.D. in Molecular Cell Biology in the Department of Cellular and Physiological Sciences at the University of British Columbia. where he developed a high content/high throughput cell based assay to identify small molecules that influence cartilage formation, and characterized several novel pathways involved in chondrogenesis. As a post-doctoral fellow, Dr. Garcha reprogrammed some of the first iPSCs from patients with bone and cartilage disorders at Toronto's SickKids Hospital in 2009, and later reprogrammed several lung tumor cell lines. This lead to Dr. Garcha's recruitment as a managing Director for the Canadian Centre for Commercialization of Regenerative Medicine's cell reprogramming and cell line engineering group. Currently he is actively providing consultative services to clients with a focus on biotechnology and healthcare, while acting as the Chief Scientific Officer of BioSEQure -a company focused on early pathogen detection and mitigation strategies.